Treatment of acute myeloid leukemia (AML) patient cells in the presence of serum with PS-ASO showed increased sensitivity to cytostatic drugs: daunorubicin or l-P-D-arabinofura-nosyl-cytosine (ara-C) [53], thereby establishing Bcl-2 PS-ASO as more clinically relevant. The gene discussed is BCL2; the disease is acute myeloid leukemia.